ATE483716T1 - Lösungsmittelfreies amorphes rapamycin - Google Patents
Lösungsmittelfreies amorphes rapamycinInfo
- Publication number
- ATE483716T1 ATE483716T1 AT05792296T AT05792296T ATE483716T1 AT E483716 T1 ATE483716 T1 AT E483716T1 AT 05792296 T AT05792296 T AT 05792296T AT 05792296 T AT05792296 T AT 05792296T AT E483716 T1 ATE483716 T1 AT E483716T1
- Authority
- AT
- Austria
- Prior art keywords
- free
- solvent
- amorphic
- rapamycin
- therapeutic agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60532404P | 2004-08-27 | 2004-08-27 | |
PCT/US2005/030606 WO2006026531A1 (en) | 2004-08-27 | 2005-08-24 | Solvent free amorphous rapamycin |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE483716T1 true ATE483716T1 (de) | 2010-10-15 |
Family
ID=35539393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05792296T ATE483716T1 (de) | 2004-08-27 | 2005-08-24 | Lösungsmittelfreies amorphes rapamycin |
Country Status (7)
Country | Link |
---|---|
US (2) | US7393952B2 (de) |
EP (1) | EP1781672B1 (de) |
JP (1) | JP5117190B2 (de) |
AT (1) | ATE483716T1 (de) |
CA (1) | CA2578245C (de) |
DE (1) | DE602005024012D1 (de) |
WO (1) | WO2006026531A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7255891B1 (en) * | 2003-02-26 | 2007-08-14 | Advanced Cardiovascular Systems, Inc. | Method for coating implantable medical devices |
US8715771B2 (en) * | 2003-02-26 | 2014-05-06 | Abbott Cardiovascular Systems Inc. | Coated stent and method of making the same |
DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
JP5528708B2 (ja) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
CN103127100A (zh) | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
US20090011117A1 (en) * | 2007-07-03 | 2009-01-08 | Endotronix, Inc. | Methods for texturing a surface of an endovascular implant |
WO2009158276A2 (en) | 2008-06-25 | 2009-12-30 | Boston Scientific Scimed, Inc. | Medical devices containing therapeutic agents |
IT1400977B1 (it) | 2010-07-01 | 2013-07-05 | Euticals Spa | Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine. |
CA2899206C (en) | 2013-01-24 | 2019-07-09 | Transderm, Inc. | Compositions for transdermal delivery of mtor inhibitors |
JP6472155B2 (ja) * | 2013-04-01 | 2019-02-20 | テルモ株式会社 | ステントおよびステントデリバリーシステム |
WO2015181826A1 (en) | 2014-05-27 | 2015-12-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Crystalline coating and release of bioactive agents |
AU2016323425B2 (en) | 2015-09-15 | 2020-10-22 | Savage Medical, Inc. | Devices and methods for anchoring a sheath in a tissue cavity |
CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
CN108129490B (zh) * | 2017-12-11 | 2020-12-01 | 成都海创药业有限公司 | 一种制备依维莫司无定形固体的方法 |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
US6384213B1 (en) * | 1998-10-23 | 2002-05-07 | Ranbaxy Laboratories Limited | Process for preparing a pure, pharmacopoeial grade amorphous form of cefuroxime axetil |
WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
CN100553677C (zh) * | 2002-04-22 | 2009-10-28 | 财团法人乙卯研究所 | 用于血管性疾病治疗的药物 |
EP2668933A1 (de) * | 2002-09-20 | 2013-12-04 | Innovational Holdings, LLC | Expandierbare medizinische Vorrichtung mit Öffnungen zur Freisetzung mehrerer Wirkstoffe |
DE10244847A1 (de) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
US20040093064A1 (en) * | 2002-11-12 | 2004-05-13 | Gjalt Bosma | Drug eluting stent graft combination |
RU2345772C2 (ru) * | 2003-07-25 | 2009-02-10 | Уайт | Лиофилизированные композиции cci-779 |
SG145716A1 (en) * | 2003-09-03 | 2008-09-29 | Wyeth Corp | Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same |
-
2005
- 2005-08-24 JP JP2007530211A patent/JP5117190B2/ja active Active
- 2005-08-24 DE DE602005024012T patent/DE602005024012D1/de active Active
- 2005-08-24 AT AT05792296T patent/ATE483716T1/de not_active IP Right Cessation
- 2005-08-24 EP EP05792296A patent/EP1781672B1/de not_active Not-in-force
- 2005-08-24 CA CA2578245A patent/CA2578245C/en not_active Expired - Fee Related
- 2005-08-24 WO PCT/US2005/030606 patent/WO2006026531A1/en active Application Filing
- 2005-08-24 US US11/210,393 patent/US7393952B2/en active Active
-
2008
- 2008-05-27 US US12/127,467 patent/US20080227982A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2578245A1 (en) | 2006-03-09 |
JP2008511642A (ja) | 2008-04-17 |
CA2578245C (en) | 2013-10-29 |
JP5117190B2 (ja) | 2013-01-09 |
US20060128739A1 (en) | 2006-06-15 |
EP1781672A1 (de) | 2007-05-09 |
EP1781672B1 (de) | 2010-10-06 |
WO2006026531A1 (en) | 2006-03-09 |
US7393952B2 (en) | 2008-07-01 |
US20080227982A1 (en) | 2008-09-18 |
DE602005024012D1 (de) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE483716T1 (de) | Lösungsmittelfreies amorphes rapamycin | |
NO20073065L (no) | Injiserbare nanopartikulaere olanzapinformuleringer | |
IL177483A0 (en) | Means for transdermal administration of nicotine | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
CR8744A (es) | Compuestos terapeuticos | |
MY148491A (en) | FUSED BICYCLIC mTOR INHIBITORS | |
UY29246A1 (es) | Nuevos compuestos | |
TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
NO20055766L (no) | Positive modulatorer av nikotinacetylcholinreseptorer | |
TW200519111A (en) | N3-substituted imidazopyridine C-KIT inhibitors | |
MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
TW200619205A (en) | A method for preparing irbesartan and intermediates thereof | |
NO20072832L (no) | Smertestillende middel | |
NO20063619L (no) | Diarylmetylpiperazinderivater, fremstilling og anvendelse derav | |
GB0416508D0 (en) | Therapeutic agents | |
BRPI0415164A (pt) | dispositivo para administrar uma composição bioterapêutica, composição bioterapêutica, método de preparação de uma composição bioterapêutica, método de tratamento, e dispensador | |
EA200700766A1 (ru) | Способ получения производных [1,4,5]-оксадиазепина | |
MY140538A (en) | Substituted n-acyl-2-aminothiazoles | |
MX2010001303A (es) | Compuestos terapeuticos. | |
DK1865931T3 (da) | Transdermal plaster | |
FR2894579B1 (fr) | Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique. | |
MX2008010804A (es) | Derivados de rapamicina para tratar neuroblastoma. | |
UA91988C2 (ru) | Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |